ILLUMINA, INC.ILMNEarnings & Financial Report
Illumina, Inc. is an American biotechnology company, headquartered in San Diego, California. Incorporated on April 1, 1998, Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. The company provides a line of products and services that serves the sequencing, genotyping and gene expression, and proteomics markets, and serves more than 155 countries.
ILMN Q4 2025 Key Financial Metrics
Revenue
$1.2B
Gross Profit
$759.0M
Operating Profit
$202.0M
Net Profit
$334.0M
Gross Margin
65.5%
Operating Margin
17.4%
Net Margin
28.8%
YoY Growth
5.0%
EPS
$2.16
Financial Flow
ILLUMINA, INC. Q4 2025 Financial Summary
ILLUMINA, INC. reported revenue of $1.2B for Q4 2025, with a net profit of $334.0M (28.8% margin). Cost of goods sold was $400.0M, operating expenses totaled $557.0M.
Key Financial Metrics
| Total Revenue | $1.2B |
|---|---|
| Net Profit | $334.0M |
| Gross Margin | 65.5% |
| Operating Margin | 17.4% |
| Report Period | Q4 2025 |
ILLUMINA, INC. Annual Revenue by Year
ILLUMINA, INC. annual revenue history includes year-by-year totals (for example, 2025 revenue was $4.3B).
| Year | Annual Revenue |
|---|---|
| 2025 | $4.3B |
| 2024 | $4.4B |
| 2023 | $4.5B |
| 2022 | $4.7B |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.08B | $1.11B | $1.08B | $1.10B | $1.04B | $1.06B | $1.08B | $1.16B |
| YoY Growth | -0.7% | 2.3% | -8.2% | -1.3% | -3.3% | -4.8% | 0.4% | 5.0% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $10.04B | $6.08B | $6.01B | $6.30B | $6.18B | $6.09B | $6.18B | $6.64B |
| Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Equity | $5.73B | $1.44B | $2.13B | $2.37B | $2.37B | $2.26B | $2.38B | $2.72B |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $77.0M | $80.0M | $316.0M | $364.0M | $240.0M | $234.0M | $284.0M | $321.0M |
More Companies
UTHR
UNITED THERAPEUTICS Corp
Revenue
$799.5M
Net Profit
$338.7M
GMAB
GENMAB A/S
Revenue
$925.0M
Net Profit
$336.0M
GH
Guardant Health, Inc.
Revenue
$265.2M
Net Profit
$-92.7M
NBIX
NEUROCRINE BIOSCIENCES INC
Revenue
$805.5M
Net Profit
$153.7M
EXEL
EXELIXIS, INC.
Revenue
$598.7M
Net Profit
$244.5M
MDGL
MADRIGAL PHARMACEUTICALS, INC.
Revenue
$287.3M
Net Profit
$-114.2M
QGEN
QIAGEN N.V.
BMRN
BIOMARIN PHARMACEUTICAL INC
Revenue
$776.1M
Net Profit
$-30.7M
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Revenue
$264.0M
Net Profit
$30.8M
BIO
BIO-RAD LABORATORIES, INC.
Revenue
$693.2M
Net Profit
$720.0M